UMass team nabs $17M from NIAID to produce HIV vaccine


As HIV researchers around the globe work to advance vaccines against the devastating virus, the NIAID has awarded $17.3 million to the University of Massachusetts Medical School’s Dr. Shan Lu and colleagues to develop and manufacture a prime-boost candidate for a midstage trial.

As part of a program spanning 7 years, Lu’s team will work to create a manufacturing process for the experimental vaccine intended to produce doses for several hundred volunteers in a Phase II trial, according to the school’s release. If successful, the team could seek to leverage that progress for a Phase III trial ranging in the thousands of doses.

After two decades in HIV research, Lu said in a statement the manufacturing validation program is the “next stage” for the vaccine candidate. The team has “made incredible progress in developing a cocktail of antigens capable of producing antibodies using our ‘prime-boost’ method,” he said.


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

The funding comes during a busy year in HIV vaccine research and on the heels of an announcement by the NIH that it’s launching a large-scale Phase IIb/III HIV vaccine trial in South Africa later this year. That study will test HVTN 100--made up of one experimental vaccine each supplied by Sanofi Pasteur and GlaxoSmithKline ($GSK)--in 5,400 HIV-uninfected men and women with 5 injections over one year.

Aside from the NIH, players large and small have committed to the effort over the past year; Aelix Therapeutics launched with $12.7 million in January and the European Commission before that committed €23 million to a public-private partnership of 22 institutions.

For their approach, Lu and colleagues joined an in-house DNA vaccine with a recombinant protein-based vaccine. They’re expecting to further revamp the shot, according to a statement, and will work with clinical supply manufacturer Waisman Biomanufacturing on the next steps.

- here’s the release

Related Articles:
NIH to launch large-scale HIV vaccine trial in South Africa
European Commission launches €23M HIV vaccine research initiative
New HIV vaccine player Aelix Therapeutics hits the scene with $12.7M Series A


Suggested Articles

Imbruvica has enjoyed a nice run in previously untreated CLL over the last few years. But major competition is here in the form of AZ's Calquence.

Pennsylvania's Supreme Court revived thousands of lawsuits alleging the antipsychotic med Risperdal caused males to develop breasts.

In the asthma biologics race, there doesn't appear to be a clear favorite among Xolair, Dupixent, Fasenra and Nucala for a group of pulmonologists.